CEO Ryan Saadi Granted 50 Million Restricted Shares Tied to $1 Billion Revenue Target
TVGN sits 57% above its 52-week low of $3.636 on light trading volume (0.3× avg).
Summary
Tevogen's CEO received 50 million restricted shares that vest only on $1.0 billion of cumulative revenue by 2031, and his reported beneficial ownership now stands at 91.1% of shares outstanding.
Key Events · Ownership and Investor Activity · TVGN
-
CEO Granted 50 Million Restricted Shares
Under the 2024 Omnibus Incentive Plan, Tevogen granted Ryan Saadi 50,000,000 restricted shares on November 2, 2026 — roughly six times the 8,000,000 restricted shares granted in September 2026.
-
Vesting Requires $1 Billion Revenue
The shares vest only on board certification of $1.0 billion in aggregate revenue from November 2, 2026 through December 31, 2031, and are automatically forfeited if the threshold is missed or service ends.
-
CEO Reports 91.1% Beneficial Ownership
Saadi reports 61,709,567 shares, or 91.1% of the 67,765,267 shares outstanding as of November 4, 2026; 59,763,101 of those are restricted and cannot be sold.
-
Thin Public Float, Concentrated Control
With the CEO reporting 91.1% of shares outstanding, the tradable float is small and public holders have minimal influence over votes and corporate actions.
Analysis · TVGN · Life Sciences
The headline number is the concentration: Saadi now reports beneficial ownership of 61,709,567 shares, or 91.1% of the 67,765,267 shares outstanding as of November 4, 2026, leaving public holders with a thin float and little say over corporate actions. That said, the award is not free money. Of those shares, 59,763,101 are restricted and cannot be sold, and the new 50,000,000-share tranche vests only if Tevogen books $1.0 billion in aggregate revenue between November 2, 2026 and December 31, 2031; miss the threshold or lose Saadi, and the shares are forfeited outright. Set that against a company that posted an $11.2M net loss and held $1.1M of cash in its August 10-Q, and the target looks like a very long reach. The practical read: the CEO's economics are now almost entirely tied to a binary outcome rather than to near-term share price.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TVGN was trading at $5.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.2M. The 52-week trading range was $3.64 to $32.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.